Table of Contents Author Guidelines Submit a Manuscript
TheScientificWorldJOURNAL
Volume 2, Pages 751-766
http://dx.doi.org/10.1100/tsw.2002.144
Mini-Review Article

Can Drug–Drug Interactions Be Predicted from In Vitro Studies?

Advanced Technology Corporation, Institute of Pathology, B23, University of LIEGE, B-4000 SART TILMAN, Belgium

Received 23 November 2001; Revised 22 January 2002; Accepted 23 January 2002

Copyright © 2002 Pierre Kremers.

Citations to this Article [17 citations]

The following is the list of published articles that have cited the current article.

  • Pierre Kremers, “In vitro Tests for Predicting Drug-Drug Interactions: The Need for Validated Procedures,” Pharmacology and Toxicology, vol. 91, no. 5, pp. 209–217, 2002. View at Publisher · View at Google Scholar
  • Sheldon H. Preskorn, “Relating Clinical Trials to Psychiatric Practice: Part II: The Gap between the Usual Patient in Registration Trials and in Practice,” Journal of Psychiatric Practice, vol. 9, no. 6, pp. 455–461, 2003. View at Publisher · View at Google Scholar
  • T. Kanazu, Y. Yamaguchi, N. Okamura, T. Baba, and M. Koike, “Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: Evaluation of cynomolgus monkeys as surrogates for humans,” Xenobiotica, vol. 34, no. 5, pp. 391–402, 2004. View at Publisher · View at Google Scholar
  • Nadege Blanchard, L. Richert, P. Coassolo, and T. Lavé, “Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration,” Current Drug Metabolism, vol. 5, no. 2, pp. 147–156, 2004. View at Publisher · View at Google Scholar
  • Zhi-Yi Zhang, and Y. Nancy Wong, “Enzyme kinetics for clinically relevant CYP inhibition,” Current Drug Metabolism, vol. 6, no. 3, pp. 241–257, 2005. View at Publisher · View at Google Scholar
  • Takushi Kanazu, Noboru Okamura, Yoshitaka Yamaguchi, Takahiko Baba, and Masahiro Koike, “Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats,” Xenobiotica, vol. 35, no. 4, pp. 305–317, 2005. View at Publisher · View at Google Scholar
  • Rhc Queiroz, Wr Malfara, and Sa Uyemura, “Correlation between dose/plasma concentration and assessment of hepatic and renal changes in Wistar rats treated with the ROM scheme,” Revista Da Sociedade Brasileira De Medicina Tropical, vol. 38, no. 2, pp. 167–172, 2005. View at Publisher · View at Google Scholar
  • Zhenquan Jia, and Hara P. Misra, “Reactive oxygen species in in vitro pesticide-induced neuronal cell (SH-SY5Y) cytotoxicity: Role of NFκB and caspase-3,” Free Radical Biology and Medicine, vol. 42, no. 2, pp. 288–298, 2007. View at Publisher · View at Google Scholar
  • Anja Bürenheide, Thomas Kunze, and Bernd Clement, “Inhibitory effects on cytochrome P450 enzymes of pentamidine and its amidoxime pro-drug,” Basic and Clinical Pharmacology and Toxicology, vol. 103, no. 1, pp. 61–65, 2008. View at Publisher · View at Google Scholar
  • Zhiyuan Xie, Tao Zhang, Jing-Fang Wang, Kuo-Chen Chou, and Dong-Qing Wei, “The computational model to predict accurately inhibitory activity for inhibitors towardsCYP3A4,” Computers in Biology and Medicine, vol. 40, no. 11-12, pp. 845–852, 2010. View at Publisher · View at Google Scholar
  • A.-E.F. Nassar, J. Du, M. Belcourt, X. Lin, and I. King, “In vitro profiling and mass balance of the anti-cancer agent laromustine [14]-vnp40101m by rat, dog, monkey and human liver microsomes,” Open Drug Metabolism Journal, vol. 4, pp. 1–9, 2010. View at Publisher · View at Google Scholar
  • M. Paul Gleeson, Sandeep Modi, Andreas Bender, Richard L. Marchese Robinson, Johannes Kirchmair, Malinee Promkatkaew, Supa Hannongbua, and Robert C. Glen, “The challenges involved in modeling toxicity data in silico: A review,” Current Pharmaceutical Design, vol. 18, no. 9, pp. 1266–1291, 2012. View at Publisher · View at Google Scholar
  • Ragini Vuppugalla, Yueping Zhang, Shu Chang, A. David Rodrigues, and Punit H. Marathe, “Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats,” Xenobiotica, vol. 42, no. 11, pp. 1058–1068, 2012. View at Publisher · View at Google Scholar
  • Xin Tian, Zhen-Yu Cheng, Han Jin, Jie Gao, and Hai-Ling Qiao, “Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats,” Evidence-Based Complementary and Alternative Medicine, 2013. View at Publisher · View at Google Scholar
  • Oraphan Phuangsawai, Supa Hannongbua, and Mathew Paul Gleeson, “Quantitative Structure-Activity Relationship (QSAR) Methods for the Prediction of Substrates, Inhibitors, and Inducers of Metabolic Enzymes,” Drug Metabolism Prediction, pp. 319–350, 2014. View at Publisher · View at Google Scholar
  • Peter J. Evans, “Maintenance of In Vivo Induced Cytochrome P-450s in Hepatocyte Monolayers at Non Freezing Temperatures,” Cryobiology, 2015. View at Publisher · View at Google Scholar
  • Katsuhito Nagai, Sho Suzuki, Ayumi Yamamura, and Hiroki Konishi, “Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol,” Biopharmaceutics & Drug Disposition, 2015. View at Publisher · View at Google Scholar